Wednesday, Aug 30, 1989
South San Francisco, Calif. -- August 30, 1989 --David Goeddel, Ph.D., has been honored as the first recipient of the Genentech Scientific Fellowship Award, which was granted by the company's Board of Directors.
"The Scientific Fellowship Award was created not only to honor extraordinary achievements that exemplify Genentech's commitment to world-class science, but to recognize efforts that have contributed in a major, direct and tangible way to Genentech's success," said Robert A. Swanson, chief executive officer. "David Goeddel certainly deserves this honor."
As one of Genentech's first employees, Goeddel greatly contributed to the company's pioneering work in genetic engineering. He has led efforts to clone and express each of Genentech's major products: human insulin, human growth hormone, interferon alpha, interferon gamma and tissue plasminogen activator ( or t-PA).
The Scientific Fellowship Award is a distinction Genentech's Board of Directors has reserved for the company's premier and prolific scientists. As director of the molecular biology department, Goeddel continues to conduct and direct leading-edge research aimed at developing novel treatments for human disorders and diseases.
As well as being the inventor or co-inventor of many important Genentech patents, Goeddel has been the recipient of many prestigious awards such as the Eli Lilly Award in Biological Chemistry in 1984, the Scheele Medal in 1988. This year, he and his Genentech colleagues, Bill Kohr, Diane Pennica and Gordon Vehar, received the Inventor of the Year award from the Intellectual Property Owners Foundation for the development of t-PA.
Goeddel currently serves on five scientific editorial boards and has written or co-written more than 100 scientific articles. He received his bachelor's degree in chemistry from the University of California at San Diego and his doctorate in biochemistry from the University of Colorado.
Genentech is a leading biotechnology company focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #